Science Corp to Begin First Human Trials of Biohybrid Brain Sensor: Shaping the Next Frontier of BCIs

Max Hodak, former Neuralink president and co-founder, launched Science Corp in 2021 with the intention of reimagining the human-machine interface. Unlike many brain-computer interface (BCI) ventures that focus solely on electronic electrodes, Science Corp is developing a biohybrid device that blends lab-grown neurons with sophisticated electronics. This approach aims to sidestep the primary drawback of current BCIs: long-term tissue damage and fading performance caused by the mechanical and electrical mismatch between rigid metal electrodes and soft brain tissue ^[1][2].

The founding team, including chief science officer Alan Mardinly and newly appointed clinical adviser Dr. Murat Günel of Yale, is steering the project away from strictly mechanical paradigms. Their reasoning is both philosophical and practical: by fostering natural connections with neurons at the device interface, the hope is to create a BCI that operates more like a biological extension rather than a foreign implant. Science Corp's vision is not just to treat disease, but to unlock augmented sensory abilities and richer brain-computer communication in the long term ^[1].

Since its inception, the company has quietly built momentum. After acquiring vision-restoration device PRIMA in 2024 and advancing it into late-stage clinical trials, Science Corp raised a $230 million Series C round in March 2026, elevating the company’s post-money valuation to $1.5 billion ^[1][4]. This strong financial backing, combined with fresh clinical talent, sets the stage for their bold entry into human trials—a key differentiator in a field dominated by high-profile, often hype-driven competitors.

Science Corp’s experimental sensor embodies a significant technical pivot from dominant BCI models. Rather than implanting metallic probes into brain tissue, as is standard with devices like Neuralink, Science Corp’s sensor will rest on the brain’s surface, beneath the skull but above the cortex, reducing invasiveness and associated risk of chronic inflammation or scar tissue ^[1][4]. The initial device features 520 recording electrodes compacted into a wafer the size of a pea, specifically designed to record and stimulate neural signals with high precision ^[1][4].

The most innovative aspect, however, lies in the integration of lab-grown neurons within the device itself. According to Mardinly’s research team, these neurons can be activated by precise pulses of light (optogenetics), with the goal of achieving a seamless biological interface. A 2024 animal study demonstrated that the device could be safely implanted in mice and effectively stimulate brain activity ^[1]. The company is now scaling up these prototypes and rigorously characterizing the neuron cultures to ensure their suitability for human therapeutic use.

Notably, the first human trials will not employ the neuron-seeded version of the device. Instead, the trials are set to evaluate the safety and efficacy of the purely electronic platform when placed on already-exposed cortex during neurosurgical procedures, such as for patients undergoing craniectomy following stroke or injury ^[4]. This staged deployment mitigates risk and allows for feedback before advancing toward the full biohybrid configuration.

A distinguishing feature of Science Corp’s initial clinical push is its therapeutic emphasis. While most BCIs concentrate on signal detection, neural decoding, or restoring lost motor controls, Science Corp’s sensor is engineered to deliver precisely targeted electrical stimulation to injured or diseased neural tissue. This marks a notable shift toward leveraging BCIs not just as assistive tech, but as active agents in neural repair ^[3][4].

The device’s first use cases are expected to revolve around patients requiring significant brain surgery, such as those with severe stroke-induced swelling. By embedding the sensor during scheduled surgical intervention, the incremental procedural risk is minimized. The stimulation paradigm is informed by decades of neurostimulation research, but the company claims that their interface could fine-tune therapy for a range of conditions—from Parkinson’s to spinal cord injuries and even neurodegenerative diseases ^[3][4].

If clinical trials validate these ambitions, Science Corp could carve a distinct niche in neurotechnology: devices not just for communication or restoration, but for regenerative healing. That would open up much wider patient populations, potentially positioning the company as a leader in medical BCI applications beyond the narrow confines of current regulatory precedents.

Science Corp’s announcement comes at a pivotal moment for the BCI industry, where multiple major players—Neuralink, Synchron, Paradromics, and others—are moving from animal data to human clinical programs. Whereas previous years focused on demonstrating technical feasibility, the competitive race is now centered on clinical data, patient benefit, and regulatory approval ^[3].

The regulatory pathway for novel neural devices remains complex. Science Corp claims that, because their sensor sits atop the brain rather than penetrating it, the device may not fall within the FDA’s highest-risk categories for experimental neurosurgery, potentially streamlining the approval process for initial implantation ^[1]. Still, the company is proactively consulting with medical ethics boards and expects further regulatory scrutiny, particularly before broader trials or commercial distribution can proceed ^[1][4].

Ultimately, Science Corp’s success will hinge on several factors: demonstrable safety, reproducible therapeutic gains for patients, long-term device stability, and ethical stewardship. The funding environment remains favorable—BCI startups attracted over $600 million in venture investment last year, underscoring the urgency and stakes of the clinical BCI race ^[3]. If Science Corp delivers on its biohybrid promise, it could fundamentally reshape expectations for how artificial and biological systems interact.